Cargando…
Biologic Therapy in Head and Neck Cancer: A Road with Hurdles
The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to...
Autores principales: | Specenier, Pol, Vermorken, Jan B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382358/ https://www.ncbi.nlm.nih.gov/pubmed/22745915 http://dx.doi.org/10.5402/2012/163752 |
Ejemplares similares
-
Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013) -
A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck
por: Specenier, Pol M, et al.
Publicado: (2009) -
Editorial: Head and neck cancer in the elderly
por: Szturz, Petr, et al.
Publicado: (2023) -
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response
por: Boeckx, Carolien, et al.
Publicado: (2014) -
Editorial: Insights in head and neck cancer: 2021
por: Lybaert, Willem, et al.
Publicado: (2023)